Table 1.
Baseline characteristics comparing the standard infusion (n = 169) and rapid infusion (n = 129) cohorts
| Variable | Standard, n (%) | Rapid, n (%) | P value |
| Male sex (%) | 76 (45.0) | 55 (42.6) | 0.72 |
| Age (yr) (median, range) | 39 (20-88) | 42 (18-86) | 0.86 |
| Low BMI (< 22 kg/m2) | 17 (10.1) | 13 (10.1) | 0.84 |
| High BMI (> 30 kg/m2) | 28 (16.6) | 31 (24.0) | 0.14 |
| Current smoker | 28 (16.6) | 26 (20.2) | 0.45 |
| Disease duration (yr) (median, range) | 7 (0-49) | 5 (0-36) | 0.78 |
| Disease type | |||
| CD | 126 (74.6) | 114 (88.4) | < 0.01 |
| UC | 43 (25.4) | 14 (10.9) | < 0.01 |
| Indeterminate | 0 (0.0) | 1 (0.8) | 0.43 |
| Extra-intestinal manifestation(s) documented | 46 (27.2) | 29 (22.5) | 0.42 |
| Psychiatric comorbidity documented | 24 (14.2) | 45 (34.9) | < 0.01 |
| Concomitant medications | |||
| Corticosteroid | 11 (6.5) | 11 (8.5) | 0.51 |
| Immunomodulator | 114 (67.5) | 104 (80.6) | 0.01 |
| Thiopurine | 91 (79.8) | 70 (67.3) | 0.04 |
| Thiopurine ADR | 32 (35.2) | 32 (45.7) | 0.20 |
| Methotrexate | 23 (20.2) | 34 (32.7) | 0.04 |
| Methotrexate ADR | 12 (52.2) | 10 (29.4) | 0.10 |
| Prior biologic | 21 (12.4) | 20 (15.5) | 0.40 |
| Other anti-TNF | 18 (85.7) | 18 (90.0) | 1.00 |
BMI: Body mass index; CD: Crohn’s disease; UC: Ulcerative colitis; ADR: Adverse drug reaction; anti-TNF: Anti-tumour necrosis factor.